Bicara Therapeutics Inc.
BCAX•NASDAQ•Healthcare•Biotechnology

About Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOClaire Mazumdar Clemon
Founded2018
IPO DateSeptember 13, 2024
Employees55
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.bicara.com
Phone617 468 4219
Address
116 Huntington Avenue, Suite 703 Boston, Massachusetts 02116 United States

Corporate Identifiers

CIK0002023658
CUSIP055477103
ISINUS0554771032
SIC2834

Leadership Team & Key Executives

Dr. Claire Mazumdar Clemon M.B.A., Ph.D.
Chief Executive Officer and Director
Ryan Cohlhepp Pharm.D.
President, Chief Operating Officer and Director
Ivan Hyep M.B.A.
Chief Financial Officer
Lara S. Meisner J.D.
Chief Legal Officer and Corporate Secretary
Pauline Dufresne
Chief People Officer
Rachel Salazar
SVice President of Research & Development Strategy and Operations
Sathish Hasige Ph.D.
Senior Vice President and Head of Technical Operations and Supply Chain
Dr. David Raben M.D.
Chief Medical Officer
Angela Windt
Vice President and Head of Regulatory Affairs
Dr. Jeltje Schulten M.B.A., M.D.
Senior Vice President of Clinical and Medical Affairs